Consultant360ACOG Releases 2026 Maternal Immunization Schedule

⚖️ Legal / Ethical Complexity

ACOG’s 2026 maternal immunization schedule, endorsed by 13 medical societies, establishes an independent evidence-based framework for vaccination before, during, and after pregnancy. Its release marks the first formal instance of ACOG issuing vaccine guidance that differs from CDC ACIP recommendations.

Professional Impact

• Routine vaccination against influenza, COVID-19, Tdap, and RSV remains recommended during pregnancy, with vaccine-specific trimester and seasonal timing guidance unchanged from prior clinical practice
• RSV vaccination is limited to 32–36 weeks in a patient’s first pregnancy; patients vaccinated in a prior pregnancy should not receive a repeat maternal dose, but their infant should receive monoclonal antibody protection after birth
• Pneumococcal, meningococcal, hepatitis A, and hepatitis B vaccines carry risk-based indications requiring individualized assessment of patient history and risk profile
• ACOG’s departure from ACIP creates potential for conflicting institutional protocols and payer coverage policies; clinicians may encounter documentation challenges when recommendations diverge from federal guidance

Action Items

• Review current vaccination protocols against ACOG’s 2026 schedule and identify any discrepancies with existing institutional or payer guidelines
• Document individualized vaccine counseling and patient risk factor assessment in the medical record, particularly for risk-based indications
• Update patient-facing materials to reflect ACOG’s guidance amid active public misinformation about maternal immunization
• Monitor payer and institutional responses to ACOG’s divergence from ACIP, as coverage determinations may lag or conflict with the new schedule